Abstract
The therapeutic efficacy of CysLT1R antagonists for the treatment of asthma and allergic rhinitis varies, with 24-78% of patients failing to show symptomatic improvement. Several in vitro studies revealed that current clinical CysLT1R antagonists block type 6 purinergic (P2Y6). However, the potential off-target effects of CysLT1R antagonists in allergic inflammation are not known.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
